| 000 | 01894 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250517040736.0 | ||
| 264 | 0 | _c20161213 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1600-0609 | ||
| 024 | 7 |
_a10.1111/ejh.12614 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMela Osorio, María J | |
| 245 | 0 | 0 |
_aLong-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. _h[electronic resource] |
| 260 |
_bEuropean journal of haematology _cApr 2016 |
||
| 300 |
_a435-42 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnemia _xetiology |
| 650 | 0 | 4 |
_aCalreticulin _xgenetics |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGene Expression |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinase 2 _xgenetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xetiology |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptors, Thrombopoietin _xgenetics |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xdrug therapy |
| 700 | 1 | _aFerrari, Luciana | |
| 700 | 1 | _aGoette, Nora P | |
| 700 | 1 | _aGutierrez, Marina I | |
| 700 | 1 | _aGlembotsky, Ana C | |
| 700 | 1 | _aMaldonado, Ana C | |
| 700 | 1 | _aLev, Paola R | |
| 700 | 1 | _aAlvarez, Clarisa | |
| 700 | 1 | _aKorin, Laura | |
| 700 | 1 | _aMarta, Rosana F | |
| 700 | 1 | _aMolinas, Felisa C | |
| 700 | 1 | _aHeller, Paula G | |
| 773 | 0 |
_tEuropean journal of haematology _gvol. 96 _gno. 4 _gp. 435-42 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/ejh.12614 _zAvailable from publisher's website |
| 999 |
_c25024687 _d25024687 |
||